- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This report highlights the key results achieved over Phase II of the MHTF, from 2014 to 2016, structured around the three cross-cutting principles of accountability, equality of access and quality of care, as outlined in the MHTF Business Plan Phase II (2014-2017). The report foregrounds the MHTF’s role in supporting health systems strengthening, and addresses its catalytic nature, its promotion of sustainability and its strong emphasis on advancing innovation.
The world has embraced the UNAIDS 90–90–90 treatment target, whereby 90% of people living with HIV know their HIV status, 90% of people who know their HIV-positive status are accessing antiretroviral treatment, and 90% of people on treatment have suppressed viral loads. By reaching the 90–90–90 treatment target by 2020, the world will be firmly on track towards ending the AIDS epidemic by 2030.
Keywords: HIV, treatment, HLM2016AIDS, ART, Fast-Track
This is the first-ever global report on treatment access to hepatitis C medicines. The report provides the information that countries and health authorities need to identify the appropriate HCV treatment, and procure it at affordable prices. The report uses the experience of several pioneering countries to demonstrate how barriers to treatment access can be overcome. It also provides information on the production of new hepatitis C drugs and generic versions worldwide, including where the drugs are registered, where the drugs are patented and where not, and what opportunities countries have under the license agreements that were signed by some companies as well as current pricing of all recommended DAAs, including by generic companies all over the world.
Keywords: HIV, hepatitis C, HCV, treatment, diagnosis, testing
Data from the DOH - Epidemiology Bureau shows that only 44o/o of allpeople diagnosed with HIV from 2010 to 2015 were started on Anti-Retroviral Therapy (ART). Based on the 2013 external evaluation of the health sector's response to HIV in the Philippines, long turn-around time of confirmatory HIV testing is one of the identified barriers for prompt referral and management. In the interim, this memorandum shall ensure linkage to care of clients with reactive HIV screening test to immediately be assessed by Treatment hubs, satellite treatment hubs and HIV primary care clinics in order to provide early treatment and management.
In 2013, viral hepatitis was a leading cause of death worldwide (1.46 million deaths, a toll higher than that from HIV, tuberculosis or malaria, and on the increase since 1990). More than 90% of this burden is due to the sequelae of infections with the hepatitis B virus (HBV) and hepatitis C virus (HCV).
Prevention can reduce the rate of new infections, but the number of those already infected would remain high for a generation. In the absence of additional efforts, 19 million hepatitis-related deaths are anticipated from 2015 to 2030. Treatment now can prevent deaths in the short- and medium term.
This year World Antibiotic Awareness Week will be held from 14 to 20 November 2016. The campaign aims to increase awareness of global antibiotic resistance and to encourage best practices among the general public, health workers, policy-makers and the agriculture sector to avoid the further emergence and spread of antibiotic resistance.
The global HIV epidemic claimed fewer lives in 2015 than at any point in almost two decades, and fewer people became newly infected with HIV than in any year since 1991. The list of countries on the brink of eliminating new HIV infections among children keeps growing. A massive expansion of antiretroviral therapy (ART) has reduced the global number of people dying from HIV-related causes to about 1.1 million in 2015 – 45% fewer than in 2005. UNAIDS/WHO estimates show that more than 18 million people were receiving ART in mid-2016.
The World Health Organization (WHO) is committed to ensuring that the great success of HIV treatment scale-up is not threatened by HIV drug resistance (HIVDR). Preventing HIVDR is an important part of meeting the 90-90-90 targets by the year 2020.
The development of a five-year plan reflects a global consensus that HIVDR in lower and middle-income countries requires a coordinated and resourced response. The Global Action Plan is an agreement by key partners about their respective roles in preventing, monitoring, and responding to HIVDR.
This infographic details the process for developing long-acting injectables for PrEP and treatment.
Keywords: HIV, ARV, PrEP, treatment, prevention, testing
With increasing global use of antiretroviral therapy (ART) to both treat and prevent HIV, and increasing global trends in HIV drug resistance ( HIVDR), efforts to improve HIV programme quality and prevent the emergence and transmission of drug-resistant HIV must be strengthened.
This global report is based on 59 countries that reported data from more than 12 000 clinics from cohorts of patients receiving ART between 2004 and 2014. The report includes the most recent clinic-level data reported to WHO in 2015 –2016 and reflects a lag due to the 12 month cohort reporting period.